The Daniel Heller Lab: Projects

Metastatic cancer is responsible for 90 percent of cancer deaths. The promise of nanomedicines for the treatment of disseminated tumors is the ability to target therapies directly to disease sites, avoiding toxic side effects by preventing accumulation in healthy tissues. We are developing new nanoparticle drug delivery systems to specifically target metastatic tumors. We collaborate with cancer biologists and clinicians to translate these therapies to the bedside.

The Heller Laboratory developed machine perception liquid biopsy (MPLB), an approach to rapidly and inexpensively detect, identify, and predict disease states from blood or other biofluids, without prior knowledge of the biomarker class that may best illuminate the disease.